La fibrose hépatique peut se développer en raison de l'inflammation chronique causée par la NAFLD.
FibroseInflammationStéatose hépatique
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque de la NAFLD ?
Les principaux facteurs incluent l'obésité, le diabète de type 2 et l'hyperlipidémie.
ObésitéDiabète de type 2Hyperlipidémie
#2
L'âge influence-t-il le risque de NAFLD ?
Oui, le risque de NAFLD augmente avec l'âge, surtout après 40 ans.
ÂgeStéatose hépatiqueFacteurs de risque
#3
Le sexe joue-t-il un rôle dans la NAFLD ?
Oui, les hommes sont généralement plus à risque de développer la NAFLD que les femmes.
SexeStéatose hépatiqueFacteurs de risque
#4
Le mode de vie sédentaire est-il un facteur de risque ?
Oui, un mode de vie sédentaire augmente le risque de NAFLD en favorisant l'obésité.
Mode de vie sédentaireObésitéStéatose hépatique
#5
Les antécédents familiaux influencent-ils le risque de NAFLD ?
Oui, des antécédents familiaux de maladies hépatiques augmentent le risque de NAFLD.
Antécédents familiauxStéatose hépatiqueFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Stéatose hépatique non alcoolique : Questions médicales les plus fréquentes",
"headline": "Stéatose hépatique non alcoolique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Stéatose hépatique non alcoolique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-15",
"dateModified": "2026-07-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique non alcoolique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Stéatose hépatique",
"url": "https://questionsmedicales.fr/mesh/D005234",
"about": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique",
"code": {
"@type": "MedicalCode",
"code": "D005234",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C06.552.241"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Stéatose hépatique non alcoolique",
"alternateName": "Non-alcoholic Fatty Liver Disease",
"code": {
"@type": "MedicalCode",
"code": "D065626",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Atsushi Nakajima",
"url": "https://questionsmedicales.fr/author/Atsushi%20Nakajima",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan."
}
},
{
"@type": "Person",
"name": "Christopher D Byrne",
"url": "https://questionsmedicales.fr/author/Christopher%20D%20Byrne",
"affiliation": {
"@type": "Organization",
"name": "Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."
}
},
{
"@type": "Person",
"name": "Vincent Wai-Sun Wong",
"url": "https://questionsmedicales.fr/author/Vincent%20Wai-Sun%20Wong",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China."
}
},
{
"@type": "Person",
"name": "Wenhao Li",
"url": "https://questionsmedicales.fr/author/Wenhao%20Li",
"affiliation": {
"@type": "Organization",
"name": "Barts Liver Centre, London, UK."
}
},
{
"@type": "Person",
"name": "William Alazawi",
"url": "https://questionsmedicales.fr/author/William%20Alazawi",
"affiliation": {
"@type": "Organization",
"name": "Barts Liver Centre, London, UK w.alazawi@qmul.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease.",
"datePublished": "2023-12-02",
"url": "https://questionsmedicales.fr/article/38042817",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01524-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vitamin E for people with non-alcoholic fatty liver disease.",
"datePublished": "2024-10-16",
"url": "https://questionsmedicales.fr/article/39412049",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015033.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Unveiling the role of gut dysbiosis in non-alcoholic fatty liver disease.",
"datePublished": "2023-10-06",
"url": "https://questionsmedicales.fr/article/37823422",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MEG.0000000000002654"
}
},
{
"@type": "ScholarlyArticle",
"name": "How non-alcoholic fatty liver disease and cirrhosis affect the heart.",
"datePublished": "2023-09-28",
"url": "https://questionsmedicales.fr/article/37770804",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12072-023-10590-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37788561",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clnu.2023.09.022"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil digestif",
"item": "https://questionsmedicales.fr/mesh/D004066"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du foie",
"item": "https://questionsmedicales.fr/mesh/D008107"
},
{
"@type": "ListItem",
"position": 4,
"name": "Stéatose hépatique",
"item": "https://questionsmedicales.fr/mesh/D005234"
},
{
"@type": "ListItem",
"position": 5,
"name": "Stéatose hépatique non alcoolique",
"item": "https://questionsmedicales.fr/mesh/D065626"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Stéatose hépatique non alcoolique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Stéatose hépatique non alcoolique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Stéatose hépatique non alcoolique",
"description": "Comment diagnostiquer la stéatose hépatique non alcoolique ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nL'échographie est-elle fiable pour diagnostiquer la NAFLD ?\nQuand une biopsie hépatique est-elle nécessaire ?\nQuels sont les critères de diagnostic de la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Stéatose hépatique non alcoolique",
"description": "Quels sont les symptômes courants de la NAFLD ?\nLa NAFLD provoque-t-elle des douleurs abdominales ?\nPeut-on avoir NAFLD sans symptômes ?\nQuels signes peuvent indiquer une progression de la NAFLD ?\nLa NAFLD peut-elle entraîner une perte de poids ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Stéatose hépatique non alcoolique",
"description": "Comment prévenir la NAFLD ?\nLe contrôle du diabète aide-t-il à prévenir la NAFLD ?\nL'alcool influence-t-il le risque de NAFLD ?\nLe stress a-t-il un impact sur la NAFLD ?\nLes bilans de santé réguliers aident-ils à prévenir la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Stéatose hépatique non alcoolique",
"description": "Quels traitements sont disponibles pour la NAFLD ?\nLes médicaments sont-ils efficaces contre la NAFLD ?\nComment l'alimentation influence-t-elle la NAFLD ?\nL'exercice physique aide-t-il à traiter la NAFLD ?\nLa perte de poids est-elle bénéfique pour la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Stéatose hépatique non alcoolique",
"description": "Quelles complications peuvent survenir avec la NAFLD ?\nLa NAFLD peut-elle entraîner une cirrhose ?\nQuels sont les risques de cancer associés à la NAFLD ?\nLa NAFLD augmente-t-elle le risque de maladies cardiovasculaires ?\nComment la fibrose est-elle liée à la NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Stéatose hépatique non alcoolique",
"description": "Quels sont les principaux facteurs de risque de la NAFLD ?\nL'âge influence-t-il le risque de NAFLD ?\nLe sexe joue-t-il un rôle dans la NAFLD ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLes antécédents familiaux influencent-ils le risque de NAFLD ?",
"url": "https://questionsmedicales.fr/mesh/D065626#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la stéatose hépatique non alcoolique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, échographies et parfois biopsies hépatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les transaminases, la bilirubine et les marqueurs de fibrose hépatique."
}
},
{
"@type": "Question",
"name": "L'échographie est-elle fiable pour diagnostiquer la NAFLD ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie est un outil non invasif efficace pour détecter la graisse hépatique."
}
},
{
"@type": "Question",
"name": "Quand une biopsie hépatique est-elle nécessaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie est envisagée si la fibrose ou la stéatose sévère est suspectée."
}
},
{
"@type": "Question",
"name": "Quels sont les critères de diagnostic de la NAFLD ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'accumulation de graisse hépatique sans consommation d'alcool significative."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la NAFLD ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, mais peut inclure fatigue, douleur abdominale et inconfort."
}
},
{
"@type": "Question",
"name": "La NAFLD provoque-t-elle des douleurs abdominales ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent ressentir une douleur ou une gêne dans la partie supérieure droite."
}
},
{
"@type": "Question",
"name": "Peut-on avoir NAFLD sans symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, beaucoup de personnes sont asymptomatiques, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Quels signes peuvent indiquer une progression de la NAFLD ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de fibrose ou de cirrhose, comme l'ictère ou l'ascite, peuvent apparaître."
}
},
{
"@type": "Question",
"name": "La NAFLD peut-elle entraîner une perte de poids ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la NAFLD est généralement associée à un gain de poids, mais des complications peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir la NAFLD ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, adopter une alimentation équilibrée et faire de l'exercice régulièrement."
}
},
{
"@type": "Question",
"name": "Le contrôle du diabète aide-t-il à prévenir la NAFLD ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon contrôle de la glycémie réduit le risque de développer la NAFLD."
}
},
{
"@type": "Question",
"name": "L'alcool influence-t-il le risque de NAFLD ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que NAFLD ne soit pas causée par l'alcool, une consommation excessive peut aggraver la condition."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur la NAFLD ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut contribuer à des comportements alimentaires malsains, augmentant le risque de NAFLD."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers aident-ils à prévenir la NAFLD ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers permettent de détecter précocement des problèmes hépatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la NAFLD ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des changements de mode de vie, comme une alimentation saine et de l'exercice."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils efficaces contre la NAFLD ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiquement approuvés pour la NAFLD."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle la NAFLD ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et pauvre en graisses saturées peut réduire la graisse hépatique."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à traiter la NAFLD ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier aide à réduire la graisse hépatique et améliore la santé globale."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle bénéfique pour la NAFLD ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids de 5 à 10 % peut améliorer significativement la condition hépatique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la NAFLD ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la fibrose, la cirrhose et le cancer du foie."
}
},
{
"@type": "Question",
"name": "La NAFLD peut-elle entraîner une cirrhose ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la NAFLD peut progresser vers une cirrhose si elle n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de cancer associés à la NAFLD ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec NAFLD ont un risque accru de développer un cancer du foie."
}
},
{
"@type": "Question",
"name": "La NAFLD augmente-t-elle le risque de maladies cardiovasculaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la NAFLD est associée à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment la fibrose est-elle liée à la NAFLD ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fibrose hépatique peut se développer en raison de l'inflammation chronique causée par la NAFLD."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de la NAFLD ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'obésité, le diabète de type 2 et l'hyperlipidémie."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de NAFLD ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de NAFLD augmente avec l'âge, surtout après 40 ans."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans la NAFLD ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes sont généralement plus à risque de développer la NAFLD que les femmes."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque de NAFLD en favorisant l'obésité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque de NAFLD ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies hépatiques augmentent le risque de NAFLD."
}
}
]
}
]
}
Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Publications dans "Stéatose hépatique non alcoolique" :
Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Publications dans "Stéatose hépatique non alcoolique" :
Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals. In this stu...
For this study, we utilized data from the National Health Insurance Research Database, patients with FLD from 2000 to 2017 were observed (follow-up until 2018). Patients were considered to have FLD if...
After 1:1 propensity-score matching, each cohort comprised 62,418 patients. The FLD cohort was further divided into NAFLD and AFLD groups, which respectively comprised 55,709 and 6709 patients. The FL...
Patients with FLD are at an increased risk of HZ development. Additionally, NAFLD is associated with a higher risk of HZ than AFLD. Therefore, patients with NAFLD should be informed of their increased...
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, affecting an estimated 3 in 10...
To evaluate the beneficial and harmful effects of vitamin E alone, or vitamin E in combination with other vitamins or minerals, versus placebo or no intervention in people with NAFLD....
We used recommended Cochrane search methods. The latest search was performed on 2 February 2024....
We included randomised clinical trials that compared vitamin E alone, or in combination with other vitamins or minerals, at any dose, duration, and route of administration, versus placebo or no interv...
Our critical outcomes were all-cause mortality, liver-related mortality, and serious adverse events. Our important outcomes were liver-related morbidity, health-related quality of life, non-serious ad...
We used Cochrane's RoB 2 tool to assess risk of bias for each of the predefined outcomes....
We used standard Cochrane methods. We used GRADE to assess the certainty of evidence....
We included 16 randomised clinical trials involving 1066 paediatric and adult participants with NAFLD. Experimental groups received vitamin E alone (14 trials) or vitamin E in combination with vitamin...
Vitamin E versus placebo or no intervention The effects of vitamin E versus placebo or no intervention on all-cause mortality (risk ratio (RR) 3.45, 95% confidence interval (CI) 0.57 to 20.86; 3 trial...
Given the very low certainty evidence, we do not know if long-term treatment (18 months to 24 months) with vitamin E administered alone affects all-cause mortality, serious adverse events, quality of ...
Three trials disclosed no external funding. Five trials were industry funded. Five trials were funded by organisations with no vested interests. Three trials did not provide any information on clinica...
Protocol: doi.org/10.1002/14651858.CD015033....
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial complicated condition, reflected by the accumulation of extra fat in the liver. A detailed study of literature throws light on the fascina...
Liver diseases affect the heart and the vascular system. Cardiovascular complications appear to be a leading cause of death in patients with non-alcoholic fatty liver disease (NAFLD) and cirrhosis. Th...
The Patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 single nucleotide polymorphism (SNP) is one of the major genetic determinant of non-alcoholic fatty liver disease (NAFLD) and is st...
PNPLA3-rs738409 SNP was genotyped in 181 patients with NAFLD who completed the EPIC Food Frequency Questionnaire. Liver steatosis was evaluated by Controlled Attenuation Parameter (CAP) (Fibroscan®530...
Overall, median age was 53 years (range 44; 62) and 60.2% of patients were male. Most subjects (56.3%) had S3 and showed increased liver stiffness (p < 0.001), AST (p = 0.003) and ALT levels (p < 0.00...
The intake of greater than or equal to 48% carbohydrate in NAFLD patients carriers of the CG/GG allele of PNPLA3 rs738409 may increase the risk of significant steatosis....
Scant West African data on non-alcoholic fatty liver disease (NAFLD) means there is little representation of this population in the modelling used to derive biomarkers and predictive indices for risk ...
A post hoc analysis of data from a cross sectional assessment of NAFLD and cardiovascular risk was performed. Data from 210 participants without significant alcohol intake, or secondary causes of fatt...
The overall accuracy of HSI, FLI, TyG index and its derivatives (TyG WHtR, TyG BMI, TyG WC) was acceptable for predicting NAFLD in this population. Given their performance in this study and in light o...
We examined the roles of type 2 diabetes (T2D) and obesity in disease activity and fibrosis progression/regression in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAF...
This multi-center, retrospective study included patients with suspected or histologically proven NAFLD/NASH from the NASH Clinical Research Network. Outcomes included disease activity and rate of fibr...
The analytical sample included 870 adult patients with baseline biopsy data and 157 patients with multiple biopsy data. Patients with NAFLD/NASH and T2D had significantly higher baseline average NAS (...
Patients with NAFLD/NASH and T2D had greater baseline disease activity versus those without T2D, but there was greater regression of disease activity over time among those with T2D. Patients with NAFL...
Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease closely linked to cardiovascular disease (CVD). This study aims to investigate the connection between early-stage NAFLD and atheroscl...
In this retrospective study, the authors analyzed data from 607 patients who underwent both coronary computed tomography angiography (CCTA) and abdominal ultrasonography (US). Logistic regression was ...
Among the 607 patients included, 237 (39.0 %) were diagnosed with NAFLD through ultrasonography. After adjusting for traditional cardiovascular risk factors, ALT, and AST, NAFLD demonstrated a signifi...
NAFLD is associated with carotid intimal thickening and non-calcified plaque, suggesting an increased cardiovascular risk. Furthermore, liver fibrosis independently increases the risk of coronary hear...
Non-alcoholic fatty liver disease (NAFLD) is a relatively common disease, and preventing its occurrence is important for both individual health and reducing social costs. Shift work is reported to hav...
Recently, significant associations between non-alcoholic fatty liver disease (NAFLD) and extra-hepatic cancer have been reported....
To carry out a comprehensive review of the current evidence in the literature on the association between NAFLD and extra-hepatic cancer....
A narrative literature review was performed through an online search for the MeSH terms "fatty liver" and "cancer" in MEDLINE (via PubMed) and LILACS (via BVS). Original studies that described the imp...
After careful analysis, nine prospective cohort studies, one retrospective cohort study, three case-control studies, and three cross-sectional studies were selected....
There is consistent evidence on the association between NAFLD and extra-hepatic carcinogenesis, especially in relation to colorectal, gastric, pancreatic, breast, prostate, and bladder cancers....
